Annual D&A
$482.90 M
+$61.90 M+14.70%
December 31, 2024
Summary
- As of February 20, 2025, REGN annual depreciation & amortization is $482.90 million, with the most recent change of +$61.90 million (+14.70%) on December 31, 2024.
- During the last 3 years, REGN annual D&A has risen by +$196.70 million (+68.73%).
- REGN annual D&A is now at all-time high.
Performance
REGN Depreciation And Amortization Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Related metrics
Quarterly D&A
$126.40 M
+$4.70 M+3.86%
December 31, 2024
Summary
- As of February 20, 2025, REGN quarterly depreciation & amortization is $126.40 million, with the most recent change of +$4.70 million (+3.86%) on December 31, 2024.
- Over the past year, REGN quarterly D&A has increased by +$13.40 million (+11.86%).
- REGN quarterly D&A is now at all-time high.
Performance
REGN Quarterly D&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Related metrics
TTM D&A
$482.90 M
+$13.40 M+2.85%
December 31, 2024
Summary
- As of February 20, 2025, REGN TTM depreciation & amortization is $482.90 million, with the most recent change of +$13.40 million (+2.85%) on December 31, 2024.
- Over the past year, REGN TTM D&A has increased by +$61.90 million (+14.70%).
- REGN TTM D&A is now at all-time high.
Performance
REGN TTM D&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Related metrics
REGN Depreciation And Amortization Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +14.7% | +11.9% | +14.7% |
| 3 y3 years | +68.7% | +11.9% | +14.7% |
| 5 y5 years | +129.6% | +11.9% | +14.7% |
REGN Depreciation And Amortization Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +68.7% | at high | +70.1% | at high | +68.7% |
| 5 y | 5-year | at high | +129.6% | at high | +132.8% | at high | +129.6% |
| alltime | all time | at high | >+9999.0% | at high | >+9999.0% | at high | >+9999.0% |
Regeneron Pharmaceuticals Depreciation And Amortization History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | $482.90 M(+14.7%) | $126.40 M(+3.9%) | $482.90 M(+2.9%) |
| Sep 2024 | - | $121.70 M(+0.8%) | $469.50 M(+3.6%) |
| Jun 2024 | - | $120.70 M(+5.8%) | $453.20 M(+4.0%) |
| Mar 2024 | - | $114.10 M(+1.0%) | $435.60 M(+3.5%) |
| Dec 2023 | $421.00 M(+23.3%) | $113.00 M(+7.2%) | $421.00 M(+3.2%) |
| Sep 2023 | - | $105.40 M(+2.2%) | $408.10 M(+3.2%) |
| Jun 2023 | - | $103.10 M(+3.6%) | $395.30 M(+7.8%) |
| Mar 2023 | - | $99.50 M(-0.6%) | $366.60 M(+7.4%) |
| Dec 2022 | $341.40 M(+19.3%) | $100.10 M(+8.1%) | $341.40 M(+8.1%) |
| Sep 2022 | - | $92.60 M(+24.5%) | $315.80 M(+6.5%) |
| Jun 2022 | - | $74.40 M(+0.1%) | $296.40 M(+1.1%) |
| Mar 2022 | - | $74.30 M(-0.3%) | $293.10 M(+2.4%) |
| Dec 2021 | $286.20 M(+21.3%) | $74.50 M(+1.8%) | $286.20 M(+4.7%) |
| Sep 2021 | - | $73.20 M(+3.0%) | $273.40 M(+5.4%) |
| Jun 2021 | - | $71.10 M(+5.5%) | $259.50 M(+5.0%) |
| Mar 2021 | - | $67.40 M(+9.2%) | $247.20 M(+4.8%) |
| Dec 2020 | $235.90 M(+12.2%) | $61.70 M(+4.0%) | $235.90 M(+3.2%) |
| Sep 2020 | - | $59.30 M(+0.9%) | $228.50 M(+2.9%) |
| Jun 2020 | - | $58.80 M(+4.8%) | $222.10 M(+3.1%) |
| Mar 2020 | - | $56.10 M(+3.3%) | $215.40 M(+2.4%) |
| Dec 2019 | $210.30 M(+41.9%) | $54.30 M(+2.6%) | $210.30 M(+5.8%) |
| Sep 2019 | - | $52.90 M(+1.5%) | $198.80 M(+9.7%) |
| Jun 2019 | - | $52.10 M(+2.2%) | $181.30 M(+11.4%) |
| Mar 2019 | - | $51.00 M(+19.2%) | $162.80 M(+9.9%) |
| Dec 2018 | $148.20 M(+1.9%) | $42.80 M(+20.9%) | $148.20 M(+5.9%) |
| Sep 2018 | - | $35.40 M(+5.4%) | $139.94 M(-1.6%) |
| Jun 2018 | - | $33.60 M(-7.7%) | $142.26 M(-1.1%) |
| Mar 2018 | - | $36.40 M(+5.4%) | $143.78 M(-1.2%) |
| Dec 2017 | $145.50 M(+39.0%) | $34.54 M(-8.4%) | $145.50 M(+4.1%) |
| Sep 2017 | - | $37.72 M(+7.4%) | $139.81 M(+7.6%) |
| Jun 2017 | - | $35.13 M(-7.8%) | $129.94 M(+8.4%) |
| Mar 2017 | - | $38.12 M(+32.1%) | $119.84 M(+14.5%) |
| Dec 2016 | $104.70 M(+39.8%) | $28.86 M(+3.6%) | $104.70 M(+6.0%) |
| Sep 2016 | - | $27.84 M(+11.2%) | $98.75 M(+7.8%) |
| Jun 2016 | - | $25.03 M(+8.9%) | $91.59 M(+11.9%) |
| Mar 2016 | - | $22.98 M(+0.3%) | $81.86 M(+9.3%) |
| Dec 2015 | $74.91 M(+42.2%) | $22.91 M(+10.8%) | $74.91 M(+13.3%) |
| Sep 2015 | - | $20.67 M(+35.1%) | $66.13 M(+11.2%) |
| Jun 2015 | - | $15.30 M(-4.5%) | $59.47 M(+4.0%) |
| Mar 2015 | - | $16.03 M(+13.4%) | $57.18 M(+8.5%) |
| Dec 2014 | $52.69 M(+27.9%) | $14.13 M(+0.9%) | $52.69 M(+5.7%) |
| Sep 2014 | - | $14.01 M(+7.6%) | $49.84 M(+6.9%) |
| Jun 2014 | - | $13.02 M(+12.9%) | $46.64 M(+7.6%) |
| Mar 2014 | - | $11.53 M(+2.1%) | $43.33 M(+5.2%) |
| Dec 2013 | $41.20 M(+11.5%) | $11.29 M(+4.5%) | $41.20 M(+3.8%) |
| Sep 2013 | - | $10.80 M(+11.3%) | $39.69 M(+3.9%) |
| Jun 2013 | - | $9.70 M(+3.1%) | $38.22 M(+0.8%) |
| Mar 2013 | - | $9.41 M(-3.8%) | $37.93 M(+2.7%) |
| Dec 2012 | $36.94 M(+18.8%) | $9.78 M(+4.8%) | $36.94 M(+5.3%) |
| Sep 2012 | - | $9.33 M(-0.9%) | $35.09 M(+3.1%) |
| Jun 2012 | - | $9.42 M(+11.9%) | $34.03 M(+4.7%) |
| Mar 2012 | - | $8.42 M(+6.2%) | $32.52 M(+4.6%) |
| Dec 2011 | $31.08 M(+57.9%) | $7.93 M(-4.2%) | $31.08 M(+6.3%) |
| Sep 2011 | - | $8.28 M(+4.7%) | $29.24 M(+13.1%) |
| Jun 2011 | - | $7.90 M(+13.2%) | $25.86 M(+15.0%) |
| Mar 2011 | - | $6.98 M(+14.7%) | $22.48 M(+14.2%) |
| Dec 2010 | $19.69 M(+38.2%) | $6.09 M(+24.4%) | $19.69 M(+6.2%) |
| Sep 2010 | - | $4.89 M(+8.2%) | $18.54 M(+7.6%) |
| Jun 2010 | - | $4.52 M(+8.2%) | $17.23 M(+9.7%) |
| Mar 2010 | - | $4.18 M(-15.2%) | $15.71 M(+10.2%) |
| Dec 2009 | $14.25 M(+26.2%) | $4.93 M(+37.5%) | $14.25 M(+19.3%) |
| Sep 2009 | - | $3.59 M(+19.7%) | $11.94 M(+7.3%) |
| Jun 2009 | - | $3.00 M(+10.1%) | $11.12 M(+0.5%) |
| Mar 2009 | - | $2.72 M(+3.7%) | $11.06 M(-2.0%) |
| Dec 2008 | $11.29 M | $2.63 M(-5.3%) | $11.29 M(-2.4%) |
| Sep 2008 | - | $2.77 M(-5.7%) | $11.56 M(-0.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2008 | - | $2.94 M(-0.2%) | $11.64 M(+0.6%) |
| Mar 2008 | - | $2.95 M(+1.6%) | $11.58 M(+0.8%) |
| Dec 2007 | $11.49 M(-21.3%) | $2.90 M(+1.4%) | $11.49 M(-4.1%) |
| Sep 2007 | - | $2.86 M(-0.5%) | $11.98 M(-6.6%) |
| Jun 2007 | - | $2.87 M(+0.7%) | $12.83 M(-6.0%) |
| Mar 2007 | - | $2.85 M(-15.9%) | $13.65 M(-6.5%) |
| Dec 2006 | $14.59 M(-5.9%) | $3.40 M(-8.4%) | $14.59 M(-3.2%) |
| Sep 2006 | - | $3.71 M(+0.5%) | $15.08 M(-1.5%) |
| Jun 2006 | - | $3.69 M(-2.8%) | $15.30 M(-0.9%) |
| Mar 2006 | - | $3.80 M(-2.1%) | $15.44 M(-0.4%) |
| Dec 2005 | $15.50 M(+0.9%) | $3.88 M(-1.4%) | $15.50 M(-0.2%) |
| Sep 2005 | - | $3.94 M(+2.7%) | $15.54 M(+0.4%) |
| Jun 2005 | - | $3.83 M(-0.7%) | $15.48 M(+0.2%) |
| Mar 2005 | - | $3.86 M(-1.5%) | $15.45 M(+0.6%) |
| Dec 2004 | $15.36 M(+18.7%) | $3.92 M(+1.0%) | $15.36 M(-2.5%) |
| Sep 2004 | - | $3.88 M(+2.1%) | $15.76 M(+1.4%) |
| Jun 2004 | - | $3.80 M(+0.6%) | $15.54 M(+7.8%) |
| Mar 2004 | - | $3.77 M(-12.5%) | $14.42 M(+11.5%) |
| Dec 2003 | $12.94 M(+53.0%) | $4.31 M(+18.0%) | $12.94 M(+21.2%) |
| Sep 2003 | - | $3.66 M(+36.5%) | $10.67 M(+16.2%) |
| Jun 2003 | - | $2.68 M(+17.1%) | $9.19 M(+5.2%) |
| Mar 2003 | - | $2.29 M(+11.7%) | $8.73 M(+3.3%) |
| Dec 2002 | $8.45 M(+39.1%) | $2.05 M(-5.5%) | $8.45 M(+2.9%) |
| Sep 2002 | - | $2.17 M(-2.6%) | $8.21 M(+8.6%) |
| Jun 2002 | - | $2.23 M(+11.0%) | $7.57 M(+12.0%) |
| Mar 2002 | - | $2.01 M(+10.9%) | $6.76 M(+11.2%) |
| Dec 2001 | $6.08 M(+37.5%) | $1.81 M(+19.2%) | $6.08 M(+9.2%) |
| Sep 2001 | - | $1.52 M(+7.0%) | $5.56 M(+7.0%) |
| Jun 2001 | - | $1.42 M(+6.8%) | $5.20 M(+7.8%) |
| Mar 2001 | - | $1.33 M(+2.5%) | $4.82 M(+9.1%) |
| Dec 2000 | $4.42 M(+30.0%) | $1.30 M(+12.3%) | $4.42 M(+9.8%) |
| Sep 2000 | - | $1.15 M(+10.4%) | $4.03 M(+6.7%) |
| Jun 2000 | - | $1.04 M(+12.9%) | $3.77 M(+4.0%) |
| Mar 2000 | - | $926.00 K(+2.9%) | $3.63 M(+6.6%) |
| Dec 1999 | $3.40 M(+13.3%) | $900.00 K(0.0%) | $3.40 M(+6.3%) |
| Sep 1999 | - | $900.00 K(0.0%) | $3.20 M(+6.7%) |
| Jun 1999 | - | $900.00 K(+28.6%) | $3.00 M(+7.1%) |
| Mar 1999 | - | $700.00 K(0.0%) | $2.80 M(-6.7%) |
| Dec 1998 | $3.00 M(-31.8%) | $700.00 K(0.0%) | $3.00 M(-11.8%) |
| Sep 1998 | - | $700.00 K(0.0%) | $3.40 M(-5.6%) |
| Jun 1998 | - | $700.00 K(-22.2%) | $3.60 M(-12.2%) |
| Mar 1998 | - | $900.00 K(-18.2%) | $4.10 M(-6.8%) |
| Dec 1997 | $4.40 M(-27.9%) | $1.10 M(+22.2%) | $4.40 M(-10.2%) |
| Sep 1997 | - | $900.00 K(-25.0%) | $4.90 M(-10.9%) |
| Jun 1997 | - | $1.20 M(0.0%) | $5.50 M(-5.2%) |
| Mar 1997 | - | $1.20 M(-25.0%) | $5.80 M(-4.9%) |
| Dec 1996 | $6.10 M(+3.4%) | $1.60 M(+6.7%) | $6.10 M(+5.2%) |
| Sep 1996 | - | $1.50 M(0.0%) | $5.80 M(-1.7%) |
| Jun 1996 | - | $1.50 M(0.0%) | $5.90 M(+1.7%) |
| Mar 1996 | - | $1.50 M(+15.4%) | $5.80 M(-1.7%) |
| Dec 1995 | $5.90 M(+40.5%) | $1.30 M(-18.8%) | $5.90 M(+1.7%) |
| Sep 1995 | - | $1.60 M(+14.3%) | $5.80 M(+9.4%) |
| Jun 1995 | - | $1.40 M(-12.5%) | $5.30 M(+8.2%) |
| Mar 1995 | - | $1.60 M(+33.3%) | $4.90 M(+16.7%) |
| Dec 1994 | $4.20 M(+35.5%) | $1.20 M(+9.1%) | $4.20 M(+7.7%) |
| Sep 1994 | - | $1.10 M(+10.0%) | $3.90 M(+8.3%) |
| Jun 1994 | - | $1.00 M(+11.1%) | $3.60 M(+9.1%) |
| Mar 1994 | - | $900.00 K(0.0%) | $3.30 M(+6.5%) |
| Dec 1993 | $3.10 M(+55.0%) | $900.00 K(+12.5%) | $3.10 M(+10.7%) |
| Sep 1993 | - | $800.00 K(+14.3%) | $2.80 M(+12.0%) |
| Jun 1993 | - | $700.00 K(0.0%) | $2.50 M(+8.7%) |
| Mar 1993 | - | $700.00 K(+16.7%) | $2.30 M(+15.0%) |
| Dec 1992 | $2.00 M(+150.0%) | $600.00 K(+20.0%) | $2.00 M(+42.9%) |
| Sep 1992 | - | $500.00 K(0.0%) | $1.40 M(+55.6%) |
| Jun 1992 | - | $500.00 K(+25.0%) | $900.00 K(+125.0%) |
| Mar 1992 | - | $400.00 K | $400.00 K |
| Dec 1991 | $800.00 K | - | - |
FAQ
- What is Regeneron Pharmaceuticals annual depreciation & amortization?
- What is the all time high annual D&A for Regeneron Pharmaceuticals?
- What is Regeneron Pharmaceuticals annual D&A year-on-year change?
- What is Regeneron Pharmaceuticals quarterly depreciation & amortization?
- What is the all time high quarterly D&A for Regeneron Pharmaceuticals?
- What is Regeneron Pharmaceuticals quarterly D&A year-on-year change?
- What is Regeneron Pharmaceuticals TTM depreciation & amortization?
- What is the all time high TTM D&A for Regeneron Pharmaceuticals?
- What is Regeneron Pharmaceuticals TTM D&A year-on-year change?
What is Regeneron Pharmaceuticals annual depreciation & amortization?
The current annual D&A of REGN is $482.90 M
What is the all time high annual D&A for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals all-time high annual depreciation & amortization is $482.90 M
What is Regeneron Pharmaceuticals annual D&A year-on-year change?
Over the past year, REGN annual depreciation & amortization has changed by +$61.90 M (+14.70%)
What is Regeneron Pharmaceuticals quarterly depreciation & amortization?
The current quarterly D&A of REGN is $126.40 M
What is the all time high quarterly D&A for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals all-time high quarterly depreciation & amortization is $126.40 M
What is Regeneron Pharmaceuticals quarterly D&A year-on-year change?
Over the past year, REGN quarterly depreciation & amortization has changed by +$13.40 M (+11.86%)
What is Regeneron Pharmaceuticals TTM depreciation & amortization?
The current TTM D&A of REGN is $482.90 M
What is the all time high TTM D&A for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals all-time high TTM depreciation & amortization is $482.90 M
What is Regeneron Pharmaceuticals TTM D&A year-on-year change?
Over the past year, REGN TTM depreciation & amortization has changed by +$61.90 M (+14.70%)